{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:10:08Z","timestamp":1790111408657,"version":"4.0.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115151","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:39:38Z","timestamp":1781800778000},"page":"115151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mitochondria-targeted delivery of bromocriptine via cerium vanadate nanocarriers for Parkinson\u2019s disease"],"prefix":"10.1016","volume":"226","author":[{"given":"Keerti","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrendra K.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrutha","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-320X","authenticated-orcid":false,"given":"Shailesh D.","family":"Dadge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafquat","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shourya","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Margarida","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-6852","authenticated-orcid":false,"given":"Ana Alexandra","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Fiadeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3395-5973","authenticated-orcid":false,"given":"Liliana","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-9307","authenticated-orcid":false,"given":"J.R.","family":"Gayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-9325","authenticated-orcid":false,"given":"Manish K.","family":"Chourasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"104","key":"10.1016\/j.ejpb.2026.115151_b0005","article-title":"Oxidative stress and mitochondrial impairment: Key drivers in neurodegenerative disorders","volume":"1","author":"Wen","year":"2025","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejpb.2026.115151_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejpb.2026.115151_b0015","unstructured":"fda, cder. Parlodel \u00ae SnapTabs \u00ae [Internet]. Available from: https:\/\/www.fda.gov\/drugsatfda."},{"issue":"58","key":"10.1016\/j.ejpb.2026.115151_b0020","article-title":"Niosomes for nose-to-brain delivery of bromocriptine: Formulation development, efficacy evaluation and toxicity profiling","volume":"1","author":"Sita","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"669","key":"10.1016\/j.ejpb.2026.115151_b0025","article-title":"Bromocriptine mesylate-loaded nanoparticles co-modified with low molecular weight protamine and lactoferrin for enhanced nose-to-brain delivery in Parkinson\u2019s disease treatment","volume":"25","author":"Cong","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115151_b0030","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1002\/anie.202011711","article-title":"A cerium vanadate nanozyme with specific superoxide dismutase activity regulates mitochondrial function and ATP Synthesis in neuronal cells","volume":"60","author":"Singh","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"issue":"108","key":"10.1016\/j.ejpb.2026.115151_b0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuint.2017.05.011","article-title":"Cerium oxide nanoparticles could ameliorate behavioral and neurochemical impairments in 6-hydroxydopamine induced Parkinson\u2019s disease in rats","volume":"1","author":"Hegazy","year":"2017","journal-title":"Neurochem. Int."},{"issue":"14","key":"10.1016\/j.ejpb.2026.115151_b0040","article-title":"Intranasal cerium oxide nanoparticles improves locomotor activity and reduces oxidative stress and neuroinflammation in haloperidol-induced parkinsonism in rats","volume":"30","author":"Mohammad","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/nano10020235","article-title":"Cerium oxide nanoparticles rescue \u03b1-synuclein-induced toxicity in a yeast model of parkinson\u2019s disease","volume":"10","author":"Ruotolo","year":"2020","journal-title":"Nanomaterials."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115151_b0050","first-page":"351","article-title":"The possible role of cerium oxide (CeO 2) nanoparticles in prevention of neurobehavioral and neurochemical changes in 6-hydroxydopamine-induced parkinsonian disease","volume":"53","author":"Hegazy","year":"2017","journal-title":"Alex. J. Med."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5152\/ABCR.2023.23150","article-title":"Cerium oxide nanoparticles rescue dopaminergic neurons in Parkinson\u2019s disease model of SH-SY5Y cells via modulating Nrf2 signaling and ameliorating apoptotic cell death","volume":"5","author":"\u00c7i\u00e7ek","year":"2023","journal-title":"Arch. Basic Clin. Res."},{"key":"10.1016\/j.ejpb.2026.115151_b0060","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.4c06616","article-title":"Cerium vanadate nanozyme with ph-dependent dual enzymatic activity for glioblastoma targeted therapy and postradiotherapy damage protection","author":"Han","year":"2024","journal-title":"ACS Nano"},{"issue":"137","key":"10.1016\/j.ejpb.2026.115151_b0065","article-title":"Rapid microwave assisted hydrothermal synthesis cerium vanadate nanoparticle and its photocatalytic and antibacterial studies","volume":"1","author":"Mishra","year":"2020","journal-title":"J. Phys. Chem. Solid"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115151_b0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1039\/D3TB01786A","article-title":"Biomedical applications of cerium vanadate nanoparticles: a review","volume":"12","author":"Farasati Far","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"23","key":"10.1016\/j.ejpb.2026.115151_b0075","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1002\/anie.201903427","article-title":"CeVO4 nanozymes catalyze the reduction of dioxygen to water without releasing partially reduced oxygen species","volume":"58","author":"Singh","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"36","key":"10.1016\/j.ejpb.2026.115151_b0080","doi-asserted-by":"crossref","first-page":"31651","DOI":"10.1021\/acsomega.2c00062","article-title":"Surface-coated cerium nanoparticles to improve chemotherapeutic delivery to tumor cells","volume":"7","author":"Pramanik","year":"2022","journal-title":"ACS Omega"},{"issue":"80","key":"10.1016\/j.ejpb.2026.115151_b0085","doi-asserted-by":"crossref","first-page":"50519","DOI":"10.1039\/C7RA06655D","article-title":"Unveiling and tackling guanidinium peptide coupling reagent side reactions towards the development of peptide-drug conjugates","volume":"7","author":"Vrettos","year":"2017","journal-title":"RSC Adv."},{"issue":"63","key":"10.1016\/j.ejpb.2026.115151_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2014.06.024","article-title":"Surface modified PLGA nanoparticles for brain targeting of Bacoside-a","volume":"15","author":"Jose","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115151_b0095","first-page":"1","article-title":"Highly sensitive validated RP-HPLC\u2013DAD method for simultaneous quantification of doxorubicin and docetaxel: augmenting industrial application","volume":"17","author":"Tiwari","year":"2025","journal-title":"Accred. Qual. Assur."},{"issue":"643","key":"10.1016\/j.ejpb.2026.115151_b0100","article-title":"Ratiometric codelivery of Paclitaxel and Baicalein loaded nanoemulsion for enhancement of breast cancer treatment","volume":"25","author":"Yadav","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115151_b0105","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2174\/1567201817666201026105611","article-title":"Repaglinide and metformin-loaded amberlite resin-based floating microspheres for the effective management of type 2 diabetes","volume":"18","author":"Jain","year":"2020","journal-title":"Curr. Drug Deliv."},{"issue":"307","key":"10.1016\/j.ejpb.2026.115151_b0110","article-title":"Designing pegylated dextran sheathed doxorubicin loaded iron nanoparticles against premenopausal breast cancer","volume":"1","author":"Tiwari","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115151_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100954","article-title":"Isolation and culturing of primary mouse astrocytes for the analysis of focal adhesion dynamics","volume":"2","author":"G\u00fcler","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.ejpb.2026.115151_b0120","doi-asserted-by":"crossref","unstructured":"\u00c7i\u00e7ek B, Dan\u0131\u015fman B. ABCResearch cerium oxide nanoparticles rescue dopaminergic neurons in Parkinson\u2019s Disease model of SH-SY5Y cells via modulating Nrf2 signaling and ameliorating apoptotic cell death. doi:10.5152\/ABCR.2023.23150.","DOI":"10.5152\/ABCR.2023.23150"},{"issue":"19","key":"10.1016\/j.ejpb.2026.115151_b0125","doi-asserted-by":"crossref","first-page":"9686","DOI":"10.1021\/acsanm.5c00545","article-title":"Neuronal Membrane-Coated Mesoporous Ceria Nanoparticles for Blood\u2212Brain Barrier Crossing and Mitigation of Neurodegeneration","volume":"8","author":"Rana","year":"2025","journal-title":"ACS Appl. Nano Mater."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115151_b0130","doi-asserted-by":"crossref","first-page":"13079","DOI":"10.1021\/acsami.2c01090","article-title":"Self-Fluorescent Lone Tryptophan Nanoparticles as Theranostic Agents against Alzheimer\u2019s Disease","volume":"14","author":"Sharma","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115151_b0135","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neulet.2010.12.014","article-title":"Curcumin I protects the dopaminergic cell line SH-SY5Y from 6-hydroxydopamine-induced neurotoxicity through attenuation of p53-mediated apoptosis","volume":"489","author":"Jaisin","year":"2011","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115151_b0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0600-0","article-title":"Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation","volume":"13","author":"Rocha","year":"2016","journal-title":"J. Neuroinflam."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1515\/jbcpp-2019-0270","article-title":"6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels","volume":"32","author":"Elyasi","year":"2020","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"issue":"49","key":"10.1016\/j.ejpb.2026.115151_b0150","doi-asserted-by":"crossref","first-page":"29228","DOI":"10.1039\/D0RA03467C","article-title":"Novel pH-sensitive and biodegradable micelles for the combined delivery of doxorubicin and conferone to induce apoptosis in MDA-MB-231 breast cancer cell line","volume":"10","author":"Rahmani","year":"2020","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115151_b0155","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tiv.2005.01.006","article-title":"Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells","volume":"19","author":"Tirmenstein","year":"2005","journal-title":"Toxicol. In Vitro"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115151_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12645-023-00176-9","article-title":"Doxorubicin-loaded polymeric nanoparticles containing ketoester-based block and cholesterol moiety as specific vehicles to fight estrogen-dependent breast cancer","volume":"14","author":"Misiak","year":"2023","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.ejpb.2026.115151_b0165","unstructured":"Hemocompatibility: Hemolysis test with medical devices (ISO 10993-4: 2017 + Amd1: 2025 and ASTM F756-17 method). - IVAMI [Internet]. [cited 2025 Sep 19]. Available from: https:\/\/www.ivami.com\/en\/biological-evaluation-of-medical-devices-medical-devices\/4943-230-hemocompatibility-hemolysis-test-iso-10993-4-2017-biological-evaluation-of-medical-devices-selection-of-tests-for-interactions-with-blood-astm-f-756-17-method."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2026.115151_b0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-8993(94)90969-5","article-title":"Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro","volume":"657","author":"Ogawa","year":"1994","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115151_b0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bmc.1349","article-title":"Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics","volume":"24","author":"Billups","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejpb.2026.115151_b0180","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8862291","article-title":"HPLC-MS\/MS-mediated analysis of the pharmacokinetics, bioavailability, and tissue distribution of schisandrol B in rats","volume":"2021","author":"Liang","year":"2021","journal-title":"Int. J. Anal. Chem."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115151_b0185","first-page":"16","article-title":"HPLC evaluation on 3-n-butylphthalide distribution","volume":"2","author":"Wang","year":"2012","journal-title":"J Appl Pharm Sci."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115151_b0190","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1021\/acschemneuro.2c00579","article-title":"UBA52 attunes VDAC1-mediated mitochondrial dysfunction and dopaminergic neuronal death","volume":"14","author":"Tiwari","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"23","key":"10.1016\/j.ejpb.2026.115151_b0195","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.3390\/cells11233770","article-title":"UBA52 is crucial in HSP90 ubiquitylation and neurodegenerative signaling during early phase of Parkinson\u2019s disease","volume":"11","author":"Tiwari","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115151_b0200","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1021\/acschemneuro.1c00797","article-title":"Angiotensin-converting enzyme 2 activation mitigates behavioral deficits and neuroinflammatory burden in 6-OHDA induced experimental models of Parkinson\u2019s disease","volume":"13","author":"Gupta","year":"2022","journal-title":"ACS Chem. Neurosci."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115151_b0205","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1007\/s11064-022-03691-0","article-title":"4-Phenylbutyrate mitigates the motor impairment and dopaminergic neuronal death during Parkinson\u2019s Disease pathology via targeting VDAC1 mediated mitochondrial function and astrocytes activation","volume":"47","author":"Tiwari","year":"2022","journal-title":"Neurochem. Res."},{"issue":"1049\u20131050","key":"10.1016\/j.ejpb.2026.115151_b0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jchromb.2017.02.028","article-title":"Determination of catecholamines and endogenous related compounds in rat brain tissue exploring their native fluorescence and liquid chromatography","volume":"1","author":"Fonseca","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2026.115151_b0215","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115151_b0220","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0600-0","article-title":"Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation","volume":"13","author":"Rocha","year":"2016","journal-title":"J. Neuroinflam."},{"issue":"MAR","key":"10.1016\/j.ejpb.2026.115151_b0225","article-title":"Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for parkinson\u2019s disease","volume":"7","author":"Esteves","year":"2015","journal-title":"Front. Aging Neurosci."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115151_b0230","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1021\/acs.bioconjchem.2c00306","article-title":"Synthesis and in vivo evaluation of a site-specifically labeled radioimmunoconjugate for dual-modal (PET\/NIRF) imaging of MT1-MMP in sarcomas","volume":"33","author":"Pringle","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2026.115151_b0235","unstructured":"Paul F. Laboratory Animal Anaesthesia [Internet]. 3rd ed. Academic Press (an imprint of Elsevier); 2009 [cited 2025 Aug 5]. Available from: https:\/\/www.fcq.unc.edu.ar\/wp-content\/uploads\/cicual\/2-laboratory_animal_anaesthesia.pdf."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/14756366.2014.920837","article-title":"Differential in vitro inhibition studies of some cerium vanadate derivatives on xanthine oxidase","volume":"30","author":"Kaya","year":"2015","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115151_b0245","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1039\/c0nr00875c","article-title":"Pharmacological potential of cerium oxide nanoparticles","volume":"3","author":"Celardo","year":"2011","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115151_b0250","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bdd.2510060305","article-title":"Pharmacokinetics and pharmacodynamics of bromocriptine in the rat","volume":"6","author":"Schran","year":"1985","journal-title":"Biopharm. Drug Dispos."},{"issue":"235","key":"10.1016\/j.ejpb.2026.115151_b0255","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: Overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"10","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115151_b0260","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12987-018-0117-2","article-title":"Benchmarking in vitro tissue-engineered blood\u2013brain barrier models","volume":"15","author":"Destefano","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ejpb.2026.115151_b0265","doi-asserted-by":"crossref","unstructured":"Ozery M, Wadhwa R. Bromocriptine. xPharm: The Comprehensive Pharmacology Reference. 2024 May 28;1\u20134. doi:10.1016\/B978-008055232-3.61348-0 PubMed PMID: 32310408.","DOI":"10.1016\/B978-008055232-3.61348-0"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02261001","article-title":"Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study","volume":"6","author":"Brannan","year":"1993","journal-title":"J. Neural Transm. Park. Dis. Dement. Sect."},{"issue":"Suppl. 3","key":"10.1016\/j.ejpb.2026.115151_b0275","article-title":"Apoptosis in Parkinson\u2019s disease: signals for neuronal degradation","volume":"53","author":"Tatton","year":"2003","journal-title":"Ann Neurol."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115151_b0280","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115151_b0285","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000279753","article-title":"Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells","volume":"91","author":"Rowther","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115151_b0290","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12264-012-1057-5","article-title":"Caspase-3 activation as a bifurcation point between plasticity and cell death","volume":"28","author":"Snigdha","year":"2012","journal-title":"Neurosci. Bull."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115151_b0295","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1460-9568.2008.06097.x","article-title":"Differential activation of PKC\u03b4 in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions","volume":"27","author":"Hanrott","year":"2008","journal-title":"Eur. J. Neurosci."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115151_b0300","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1007\/s12035-023-03331-w","article-title":"CtBP neuroprotective role in toxin-based Parkinson\u2019s disease models: from expression pattern to dopaminergic survival","volume":"60","author":"Saraiva","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115151_b0305","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.ymthe.2022.06.003","article-title":"MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson\u2019s disease","volume":"30","author":"Esteves","year":"2022","journal-title":"Mol. Ther."},{"issue":"101","key":"10.1016\/j.ejpb.2026.115151_b0310","article-title":"On the axonal transport of lipid nanoparticles in primary hippocampal neurons","volume":"1","author":"Martins","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"6462","key":"10.1016\/j.ejpb.2026.115151_b0315","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw9997","article-title":"Axonal transport: driving synaptic function","volume":"366","author":"Guedes-Dias","year":"2019","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0320","article-title":"Rapid growth cone uptake and dynein-mediated axonal retrograde transport of negatively charged nanoparticles in neurons is dependent on size and cell type","volume":"15","author":"Lesniak","year":"2018","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.ejpb.2026.115151_b0325","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1444","article-title":"Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety","volume":"9","author":"Rzigalinski","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0330","first-page":"274","article-title":"Effects of bromocriptine and\/or L-DOPA on neurons in substantia nigra of MPTP-treated CS7BL\/6 mice","volume":"728","author":"Fukuda","year":"1996","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115151_b0335","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1021\/acsnano.5b08045","article-title":"Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheime\u0155s disease","volume":"10","author":"Kwon","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejpb.2026.115151_b0340","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1196\/annals.1403.015","article-title":"Treatment of neurodegenerative disorders with radical nanomedicine","volume":"1122","author":"Singh","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115151_b0345","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejpb.2026.115151_b0350","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson\u2019s disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115151_b0355","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.freeradbiomed.2011.06.006","article-title":"Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia","volume":"51","author":"Estevez","year":"2011","journal-title":"Free Radic. Biol. Med."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:44:00Z","timestamp":1790109840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":71,"alternative-id":["S0939641126001724"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115151","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitochondria-targeted delivery of bromocriptine via cerium vanadate nanocarriers for Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115151"}}